The global colorectal cancer diagnostics market size is calculated at USD 16.90 billion in 2025 and is forecasted to reach around USD 36.07 billion by 2034, accelerating at a CAGR of 8.80% from 2025 to 2034. The North America colorectal cancer diagnostics market size surpassed USD 6.21 billion in 2024 and is expanding at a CAGR of 8.82% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Colorectal Cancer Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Colorectal Cancer Diagnostics Market, by Test Type
8.1.1. Blood Test
8.1.1.1. Market Revenue and Forecast
8.1.2. Stool Test
8.1.2.1. Market Revenue and Forecast
8.1.3. Fecal Occult Blood Test (FOBT)
8.1.3.1. Market Revenue and Forecast
8.1.4. Fecal Biomarker Test
8.1.4.1. Market Revenue and Forecast
8.1.5. CRC DNA Screening Test
8.1.5.1. Market Revenue and Forecast
8.1.6. Imaging Test
8.1.6.1. Market Revenue and Forecast
8.1.7. Computed Tomography (CT) scan
8.1.7.1. Market Revenue and Forecast
8.1.8. Ultrasound
8.1.8.1. Market Revenue and Forecast
8.1.9. Magnetic Resonance Imaging (PET) scan
8.1.9.1. Market Revenue and Forecast
8.1.10. Positron Emission Tomography (PET) scan
8.1.10.1. Market Revenue and Forecast
8.1.11. Colonoscopy
8.1.11.1. Market Revenue and Forecast
8.1.12. Other Imaging Tests
8.1.12.1. Market Revenue and Forecast
8.1.13. Biopsy
8.1.13.1. Market Revenue and Forecast
8.1.14. Other Test Types
8.1.14.1. Market Revenue and Forecast
9.1. Colorectal Cancer Diagnostics Market, by End-use
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast
9.1.2. Diagnostic Imaging Centers
9.1.2.1. Market Revenue and Forecast
9.1.3. Cancer Research Centers
9.1.3.1. Market Revenue and Forecast
9.1.4. Others
9.1.4.1. Market Revenue and Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Test Type
10.1.2. Market Revenue and Forecast, by End-use
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Test Type
10.1.3.2. Market Revenue and Forecast, by End-use
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Test Type
10.1.4.2. Market Revenue and Forecast, by End-use
10.2. Europe
10.2.1. Market Revenue and Forecast, by Test Type
10.2.2. Market Revenue and Forecast, by End-use
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Test Type
10.2.3.2. Market Revenue and Forecast, by End-use
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Test Type
10.2.4.2. Market Revenue and Forecast, by End-use
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Test Type
10.2.5.2. Market Revenue and Forecast, by End-use
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Test Type
10.2.6.2. Market Revenue and Forecast, by End-use
10.3. APAC
10.3.1. Market Revenue and Forecast, by Test Type
10.3.2. Market Revenue and Forecast, by End-use
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Test Type
10.3.3.2. Market Revenue and Forecast, by End-use
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Test Type
10.3.4.2. Market Revenue and Forecast, by End-use
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Test Type
10.3.5.2. Market Revenue and Forecast, by End-use
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Test Type
10.3.6.2. Market Revenue and Forecast, by End-use
10.4. MEA
10.4.1. Market Revenue and Forecast, by Test Type
10.4.2. Market Revenue and Forecast, by End-use
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Test Type
10.4.3.2. Market Revenue and Forecast, by End-use
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Test Type
10.4.4.2. Market Revenue and Forecast, by End-use
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Test Type
10.4.5.2. Market Revenue and Forecast, by End-use
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Test Type
10.4.6.2. Market Revenue and Forecast, by End-use
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Test Type
10.5.2. Market Revenue and Forecast, by End-use
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Test Type
10.5.3.2. Market Revenue and Forecast, by End-use
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Test Type
10.5.4.2. Market Revenue and Forecast, by End-use
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. BioMerieux SA
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Dickinson and Company
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. GE Healthcare
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Qiagen N.V
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Thermo Fischer Scientific
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Hologic Inc
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Epigenomics AG
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. F-Hoffmann-La Roche Ltd
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Siemens Healthineers
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample